Interview with Thierry Poiraud, General Manager, Menarini France
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Address: Menarini Building 1 rue du Jura 94633 Rungis Cedex BP 40528, France
Tel: 01 45 60 77 20
Web: http://www.menarini.fr/accueil/
Menarini started up its operations in Feb 1992 with a product portfolio acquired through an exchange of products with Sanofi. From this base, the affiliate ventured onto the French market and in 1993 it launched an original gel with analgesic and anti-inflammatory properties, and in a few months time it became the leader in this therapeutic class. Three innovative cardiovascular products have been launched successively in 2002 and 2004.
MENARINI, 1 Italian pharmaceutical group, today operates in over 100 countries. With over 2.6 billion euros in turnover, 12 500 employees, the Menarini Group is the 20th in European rankings and 36th in the world rankings.
France: 112.5 million euros in 2008; employs 600 (heavy growth in last 5 years, double # last 3 years and wants 150m euro for 2010)
Distribution of turnover: 30% Self-Medication – Ethical Drugs 70%
Commercial/Mkting autonomy for HQ
2 launches in 2009: cardiology, angina pectoris
Sports medicine and Rhumatology in France
Present in the most important therapeutic areas of greatest importance, including:
• Cardiovascular Products
• Gastro-intestinal Products
• Antibiotics / Respiratory System Products
• Diabetes
• Anti-inflammatory agents / Analgesics
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of…
Anne-Marie Noir discusses footcare, Laboratoires Asepta’s corporate values, the strategic development behind their innovative brand, and the company’s positioning in Monaco. She also discusses her family’s legacy in the business…
Carlos Jaime, Head of Samsung’s Health & Medical Equipment Division, France, explains why the future of healthcare is in mobile technology and communications, and how Samsung’s expertise in “digital transformations”…
Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current…
Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake…
Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry…
Eric Le Roy, CEO of the SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The National Association of Medical Technologies Industry), reveals how the French medical devices market is valued at…
Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has…
Jean-Luc Bélingard, chairman of bioMérieux, reveals how the medical community in France has a unique profile, combining both clinical and technological experience, leading to what he describes as the best…
Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device…
Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014:…
While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research.…
See our Cookie Privacy Policy Here